Cardiotoxicity. The study population will consist of patients diagnosed with cancer, without history of heart failure and LV ejection fraction (EF) ≥ 50%, scheduled for high dose anthracyclines (doxorubicin ≥240 mg/m2 or epirubicin ≥360 mg/m2) as standard of care (SoC) systemic anticancer treatment.

• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardioto … Recruiting
  2024-515495-13-00 5 2023-07-06

Showing 1–1 of 1 trials